The proposal continues our objective to elucidate the molecular events that control acute systemic inflammation, a highly lethal process. In the previous grant cycle, we discovered a Toll like receptor (TLR) - driven, temportally-defined, epigenetic program in innate immunity macrophages and neutrophis, which directs the course of acute systemic inflammation. This process modifies chromatin structure to repress or activate distinct functional sets of genes, thus generating distinct phenotypic phases. Others and we have shown that bioenergy shifts also occur in innate immunity cells during acute systemic inflammation. This application develops the unified concept that modifications in bioenergetics integrate with epigenetics to direct the phase shifts of acute inflammation. We propose two specific aims:
Aim 1) To define the connections between bio-energy and epigenetics. We will use a cell model that reproduces TLR4-dependent phase shifts to: a) delineate gene-specific chromatin modifications;b) determine protein-protein interactions;c) assess metabolic profiles by mass spectroscopy;and c) translate our concept to human normal and sepsis blood leukocytes.
Aim 2) To test effects of modifying bio-energy and epigenetic shift on clinical outcomes. We will us a murine model of sepsis to: a) define bio-energy and epigenetic phase shifts, using biochemical and genetic methods to analyze plasma and isolated leukocytes from spleen, peritoneum, and bone marrow;and b) use pharmacologic and genetic approaches to determine whether modifying to adaptive phase alters microvascular inflammation and survival. Our result will broadly impact the field of inflammation by providing new insight on how acute inflammation is orchestrated, and inform novel therapies.
Acute systemic inflammation is a major health care problem, killing ~300,000/ yr in USA. No effective therapies exist for altering the inflammatory component of the disease. This research will provide new insight into the molecular events that coordinate the temporal features of sepsis, and enable design of therapies.
|Vachharajani, Vidula T; Liu, Tiefu; Brown, Candice M et al. (2014) SIRT1 inhibition during the hypoinflammatory phenotype of sepsis enhances immunity and improves outcome. J Leukoc Biol 96:785-96|
|Vachharajani, Vidula; Liu, Tiefu; McCall, Charles E (2014) Epigenetic coordination of acute systemic inflammation: potential therapeutic targets. Expert Rev Clin Immunol 10:1141-50|
|Liu, Yongmei; Ding, Jingzhong; Reynolds, Lindsay M et al. (2013) Methylomics of gene expression in human monocytes. Hum Mol Genet 22:5065-74|
|Brudecki, Laura; Ferguson, Donald A; McCall, Charles E et al. (2013) Mitogen-activated protein kinase phosphatase 1 disrupts proinflammatory protein synthesis in endotoxin-adapted monocytes. Clin Vaccine Immunol 20:1396-404|
|Liu, Tie Fu; McCall, Charles E (2013) Deacetylation by SIRT1 Reprograms Inflammation and Cancer. Genes Cancer 4:135-47|
|Millet, Patrick; McCall, Charles; Yoza, Barbra (2013) RelB: an outlier in leukocyte biology. J Leukoc Biol 94:941-51|
|Hoth, J Jason; Wells, Jonathan D; Yoza, Barbara K et al. (2012) Innate immune response to pulmonary contusion: identification of cell type-specific inflammatory responses. Shock 37:385-91|
|Brudecki, Laura; Ferguson, Donald A; Yin, Deling et al. (2012) Hematopoietic stem-progenitor cells restore immunoreactivity and improve survival in late sepsis. Infect Immun 80:602-11|
|Yoza, Barbara K; McCall, Charles E (2011) Facultative heterochromatin formation at the IL-1 beta promoter in LPS tolerance and sepsis. Cytokine 53:145-52|
|McCall, Charles E; El Gazzar, Mohamed; Liu, Tiefu et al. (2011) Epigenetics, bioenergetics, and microRNA coordinate gene-specific reprogramming during acute systemic inflammation. J Leukoc Biol 90:439-46|
Showing the most recent 10 out of 25 publications